Biography
Claudio Nicolini was born in Udine, Italy. He received the doctoral degree in physics from the University of Padua, in 1967. After serving as Adjunct Professor at the University of Bari, he moved for 17 years to the United States, of which he became citizen since 1974, and was originally at Brown University, MIT, and BNL. He then moved to Temple University School of Medicine, Philadelphia, where after a period of intensive training and research in pathology he became Associate Professor of Pathology and then Professor and Chairman of the Biophysics in 1976. In 1985, he was called as “eminent scientist†to the Chair of Biophysics of the University of Genoa, in Italy until 2012, where he was successively Director of Biophysics Institute, DISTBIMO and CIRSDNNOB. From 1993 until now is Life President of the Fondazione ELBA Nicolini and of the Nanoworld Institute. On 2008 has been elected as a Foreign Member of the Russian Academy of Sciences and on 2010 Honoris Causa Professor of Biophysics and Nanobiotechnology at Moscow State University. He was Chief Editor of Cell Biophysics (USA), Science and Technology Advisor to Italian Prime Minister Craxi, Member of the National Science and Technology Council upon Parliament election, Scientific Director Industrial Consortium CIREF, Founder Technobiochip; President Polo National Bioelectronics, President Scientific Technological Park of Elba Island. He received several awards and prizes and has authored more than 480 publications in international scientific journals (SCI), 35 patents (WPI), 28 books and Series Editor in Bioelectronics (Plenum) and Nanobiotechnology (Pan Stanford). His main scientific activities concerned cancer research, biophysics and nanotechnology, pioneering world-wide chromatin structure-function, bioelectronics and nanobiotechnology.
Research Interest
Cancer research, Biophysics and Nanotechnology, pioneering world-wide chromatin structure-function, Bioelectronics and Nanobiotechnology.
Biography
Dr. Alain Moreau is Full Professor in the Faculty of Dentistry and the Faculty of Medicine at the Universite de Montreal. He is the Director of Research and Chief Scientific Officer of Sainte-Justine University Hospital.Dr. Moreau received his PhD in Microbiology and Immunology from the Universite de Montreal in 1993. He did a first postdoctoral training at the Protein Engineering Center of University of Liege, Belgium (1992-1993), followed by a second postdoctoral fellowship at the Shriners Hospital for Children in Montreal affiliated with McGill University (1993-1997). Dr. Moreau is an internationally recognized expert on molecular genetics of pediatric scoliosis and osteoarthritis. His discoveries led to multiple peer-reviewed papers, international conferences as guest speaker, several awards as well as 32 patents issued.
Research Interest
Protein engineering, Molecular genetics, Biomarkers
Biography
Chee Gee See is the Director of Personalised Medicine at Proteome Sciences, a company providing high end mass-spectrometry based biomarker discovery and clinical utility tools, uniquely positioned to engage with pharma partners in our quest for personalised medicines. CheeGee was previously the clinical Biomarker and Experimental Medicine Leader at Roche for 5 years. He was the BEML for the Phase III pivotal TOGA study where Herceptin was trialled for the new indication of gastric cancer. He was also a BEML for CVD, CNS and immunology so his range and awareness of disease areas and their clinical development challenges is both deep and broad. CheeGee also spent 11 years at GSK where he was a genetics expert covering 3 key therapeutic areas in preclinical research within Genetics Research Europe. Prior to industry, CheeGee spent 6 years in post-doctoral academia at the University of Birmingham and University College London, most notably in the Human Genome Mapping Project. CheeGee also has dual specialist expertise as a consultant in regulatory affairs and value-based drug pricing, reimbursement and market access. CheeGee looks forward to engaging with like-minded professionals during this conference.
Research Interest
Personalised Medicine, biomarkers, genetics